معرفی
Roy S. Herbst is an Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology at Yale University, serving as Deputy Director of the Yale Cancer Center and Chief of Hematology/Medical Oncology at Smilow Cancer Hospital. His work focuses on lung cancer, personalized medicine, and immunotherapy, particularly linking genetic abnormalities to novel therapies. He leads major clinical trials like Lung-MAP and has pioneered biomarker-driven approaches, leading to FDA approvals for therapies like osimertinib.
Education & Training:
- B.S. and M.S., Molecular Biophysics & Biochemistry, Yale University (1984)
- M.D., Cornell University Medical College (1991)
- Ph.D., Molecular Cell Biology, Rockefeller University (1990)
- Fellowships: Dana-Farber Cancer Institute and Brigham and Women’s Hospital
Research Interests: Dr. Herbst’s research emphasizes translational oncology, including developmental therapeutics, biomarkers, and adaptive immune responses. He focuses on EGFR inhibitors, immunotherapy combinations, and mechanisms of resistance to targeted therapies. His work integrates clinical, laboratory, and population health approaches to improve lung cancer outcomes.
- Key areas: Lung cancer biology, biomarker-driven trials, PD-L1 inhibitors, KRAS mutations
- Leads initiatives like the Lung-MAP master protocol and SPORE grants
Awards & Recognition:
- Giants of Cancer Care Award (2022)
- AACR Distinguished Public Service Award (2020)
- Paul A. Bunn, Jr. Scientific Award (2016)
- 2018 Team Science Award (ACTS)
Grants & Leadership: Principal investigator for NCI-funded SPORE grants (2015, 2020), Lung-MAP trial leader, and co-leader of BATTLE trials. Serves as Vice Chair of SWOG Lung Committee and chairs AACR’s Scientific Policy Committee. His work has driven FDA approvals and policy changes in personalized oncology.
Labs & Teams: Leads the Yale Cancer Center’s thoracic oncology program, collaborating with teams like the Human and Translational Immunology Program. His lab focuses on tumor microenvironment dynamics and immune checkpoint inhibitors.